In addition to imaging tools, emerging biomarkers like fibroblast growth factor-21 (FGF-21) and cytokeratin-18 (CK-18) have shown potential to reflect metabolic dysfunction and liver injury, particularly in MASLD. The gene discussed is FGF21; the disease is metabolic dysfunction-associated steatotic liver disease.